Immunic (IMUX) Research & Development (2013 - 2026)

Immunic has disclosed Research & Development across 14 years of filings, most recently posting $25.6 million for Q1 2026.

• Research & Development for Q1 2026 came in at $25.6 million, up 19.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.1 million (up 3.9% YoY), and the FY2025 annual result was $82.0 million, up 2.42% from the prior year.
• Research & Development came in at $25.6 million for Q1 2026 at Immunic, up from $19.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $25.6 million in Q1 2026 to a low of $16.5 million in Q3 2022.
• The 5-year median for Research & Development is $20.0 million (2025), against an average of $20.1 million.
• Across the five-year window, Research & Development soared 51.45% in 2022 and fell 18.41% in 2024, its largest moves.
• Immunic's Research & Development stood at $20.7 million in 2022, then declined by 7.0% to $19.3 million in 2023, then increased by 12.1% to $21.6 million in 2024, then declined by 11.79% to $19.1 million in 2025, then jumped by 34.39% to $25.6 million in 2026.
• The last three Research & Development figures came in at $25.6 million (Q1 2026), $19.1 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.